• Denali Therapeutics disclosed topline results from the Phase 2b LUMA study of BIIB122 (DNL151) in early-stage Parkinson’s disease, with detailed findings set for presentation at a future scientific conference.
• The trial failed to show a clinical benefit versus placebo, missing both the main goal and key follow-on measures.
• Biogen and Denali will stop further development of BIIB122 for idiopathic Parkinson’s disease, despite the drug showing expected biological activity signals and an acceptable safety profile.
• Denali will continue the Phase 2a BEACON study in Parkinson’s patients who carry a pathogenic LRRK2 variant, with data expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.